0001415889-24-004123.txt : 20240216 0001415889-24-004123.hdr.sgml : 20240216 20240216162106 ACCESSION NUMBER: 0001415889-24-004123 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240214 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Palleiko Benjamin L CENTRAL INDEX KEY: 0001366244 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 24648679 MAIL ADDRESS: STREET 1: C/O KALVISTA PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, BLD 200, STE 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: Palleiko Ben DATE OF NAME CHANGE: 20060615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4 1 form4-02162024_090252.xml X0508 4 2024-02-14 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001366244 Palleiko Benjamin L C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 false true false false CFO, CBO 0 Common Stock 2024-02-14 4 S 0 40855 15.0093 D 159088 D The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. /s/ Benjamin L. Palleiko 2024-02-16